Dengue viruses cause dengue outbreaks and major epidemics in most tropical and subtropical areas where Aedes albopictus and Aedes aegypti mosquitoes are abundant. Among the arthropod-borne flaviviruses, the four dengue virus serotypes, dengue type 1 virus (DENV-1), dengue type 2 virus (DENV-2), dengue type 3 virus (DENV-3), and dengue type 4 virus (DENV-4) are most important in terms of human morbidity and geographic distribution.
A safe and effective vaccine against dengue is currently not available. Passive immunization with monoclonal antibodies from non-human primates or humans represents a possible alternative to vaccines for prevention of illness caused by dengue virus. Researchers at NCI's Cancer and Inflammation Program developed fully human monoclonal antibodies that bind and neutralize dengue type 1, 2, 3 and 4 viruses, as well as fragments of such antibodies and nucleic acids encoding the antibodies of the technology, and prophylactic, therapeutic and diagnostic methods employing the antibodies and nucleic acids of the invention.
- Prophylaxis/therapy against dengue serotypes 1, 2, 3, and 4;
- Dengue diagnostics.
- Antibodies are cross-reactive with all four serotypes of dengue;
- Antibodies are fully human.
Dimiter S. Dimitrov (NCI), Zhongyu Zhu (NCI)
V. Puri et al. [PMID: 23765162]
- U.S. Patent Issued: U.S. Patent Number 9556254, Filed 12 Nov 2014, Issued 31 Jan 2017